Latest news with #LabSimple
Associated Press
19-05-2025
- Business
- Associated Press
Industry Veterans Jill Thompson and Harold Kisner to Join CLEU Diagnostics Advisory Board to Launch LabSimple Platform
PHILADELPHIA--(BUSINESS WIRE)--May 19, 2025-- CLEU Diagnostics, the company reimagining comprehensive clinical laboratory testing has expanded its commercial advisory board with the additions of Jill Thompson and Harold Kisner PhD, MBA. Ms. Thompson and Dr. Kisner combined have five decades of experience in commercializing first-in-kind diagnostic technology. Ms. Thompson is the principal at JoLT Group, a consulting practice focused on the Life Sciences and Diagnostics where she spent years leading teams through startups, turnarounds, product development and commercialization. Her extensive rolodex of strategics, investment bankers, industry analysts, and key opinion leaders has led to multiple licensing deals, joint ventures, and mergers and acquisitions. 'LabSimple checks all the boxes and is really a culmination of what we as an industry have been hoping to achieve for a long time.', said Ms. Thompson. Dr. Kisner is an accomplished strategic leader and company builder with significant experience in the laboratory diagnostics industry. As a nationally recognized expert in clinical laboratory operations and workflow automation, Dr. Kisner brings deep domain expertise to integrated health systems, academic medical centers, and large physician group practices across the U.S. He previously served as Chief Operating Officer and Laboratory Director for Path Lab Inc, one of the fastest growing integrated health network laboratories, as well as Chief Laboratory Officer for Davita Laboratories. 'The remarkable capability of LabSimple makes it possible to introduce extremely advanced laboratory techniques into any market that would usually only be possible with large expensive purpose-built instruments. This is an exciting advancement for our industry, as it enables numerous applications that were previously not thought to be possible for a point of care style device.', said Dr. Kisner. Visit us at View source version on CONTACT: Investor and Media Inquiries [email protected] KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES TECHNOLOGY OTHER SCIENCE GENERAL HEALTH SCIENCE HARDWARE SOURCE: CLEU Diagnostics Copyright Business Wire 2025. PUB: 05/19/2025 08:07 AM/DISC: 05/19/2025 08:06 AM
Business Wire
19-05-2025
- Business
- Business Wire
Industry Veterans Jill Thompson and Harold Kisner to Join CLEU Diagnostics Advisory Board to Launch LabSimple Platform
PHILADELPHIA--(BUSINESS WIRE)--CLEU Diagnostics, the company reimagining comprehensive clinical laboratory testing has expanded its commercial advisory board with the additions of Jill Thompson and Harold Kisner PhD, MBA. Ms. Thompson and Dr. Kisner combined have five decades of experience in commercializing first-in-kind diagnostic technology. Ms. Thompson is the principal at JoLT Group, a consulting practice focused on the Life Sciences and Diagnostics where she spent years leading teams through startups, turnarounds, product development and commercialization. Her extensive rolodex of strategics, investment bankers, industry analysts, and key opinion leaders has led to multiple licensing deals, joint ventures, and mergers and acquisitions. 'LabSimple checks all the boxes and is really a culmination of what we as an industry have been hoping to achieve for a long time.', said Ms. Thompson. Dr. Kisner is an accomplished strategic leader and company builder with significant experience in the laboratory diagnostics industry. As a nationally recognized expert in clinical laboratory operations and workflow automation, Dr. Kisner brings deep domain expertise to integrated health systems, academic medical centers, and large physician group practices across the U.S. He previously served as Chief Operating Officer and Laboratory Director for Path Lab Inc, one of the fastest growing integrated health network laboratories, as well as Chief Laboratory Officer for Davita Laboratories. 'The remarkable capability of LabSimple makes it possible to introduce extremely advanced laboratory techniques into any market that would usually only be possible with large expensive purpose-built instruments. This is an exciting advancement for our industry, as it enables numerous applications that were previously not thought to be possible for a point of care style device.', said Dr. Kisner. About LabSimple LabSimple is a next generation point-of-care style diagnostic platform designed as an all-in-one replacement for the clinical laboratory while being simple enough for anyone to use without training. LabSimple is disruptive because it has the unusual combination of being comprehensive, high performance, simple, and low cost. About CLEU Diagnostics CLEU Diagnostics was founded in 2018 by a group of renowned physicians with the goal of transforming healthcare through innovation. LabSimple is a disruptive, next generation technology that will redefine the $110B US clinical lab testing market.
Associated Press
17-03-2025
- Business
- Associated Press
Former Alere and LumiraDx R&D Chief Nigel Lindner Joins CLEU Diagnostics to Launch Revolutionary LabSimple Diagnostic Platform
CLEU Diagnostics, the company reimagining comprehensive clinical laboratory testing has expanded its team with the addition of Nigel Lindner, PhD as Chief Innovation Officer. Dr. Lindner brings over three decades of experience in advancing innovation in diagnostics, previously as Global Head of R&D at Alere, CEO of Swiss Precision Diagnostics, and CIO at LumiraDx. 'We are incredibly excited about the opportunity to work closely with Dr. Lindner to validate and bring to market this game changing technology,' said Andrew Fleischman, MD, CEO of CLEU Diagnostics. In joining CLEU Diagnostics, Nigel continues a long career in pursuit of introducing simplicity to lab-quality diagnostic testing. Today, most lab testing is performed by skilled technicians at specialized central laboratories. However, there has been a longstanding vision for comprehensive lab testing to become simple enough to fit into a small portable module that can be used by just about anyone, anywhere. That vision for accessible lab testing will soon become a reality with LabSimple. 'A comprehensive platform that seamlessly integrates a range of diagnostic modalities to bring high-quality core lab testing to the point of need while also being uniquely cost competitive for widespread use has long been a vision for the future of healthcare. The remarkable team at CLEU Diagnostics has solved the key challenges to make this vision a reality. There is going to be a lot of excitement once the magnitude of the achievement of LabSimple becomes better understood by the healthcare industry,' said Dr. Lindner. The exceptional versatility of LabSimple enables complex analytical techniques, such as chemistry, microscopy, flow cytometry, and single photon counting, to be performed with low cost instruments and disposable test cartridges. Instrument modules, about the size of an iPhone, are stackable to deliver scalable test throughput in any location. Innovation in fabrication of cartridges for complex test panels maximizes manufacturing output to deliver at an ultra-low price point. For the first time, comprehensive point-of-care style testing can be implemented at a cost comparable to a large central laboratory. 'Our platform is not one size fits all. We can engineer low-cost cartridges to meet the unique requirements of each application. The platform has also been designed from the ground up – we created an advanced microfluidic control system, a new technology that facilitates miniaturization of complex analytical systems, such as flow cytometry, that are normally much larger and more expensive,' said Kam Ghofrani, Lead Engineer for CLEU. LabSimple will launch beginning in late 2026: Respiratory Viral Panel (Molecular Diagnostics) Complete Blood Count (Hematology) Basic Metabolic Panel (Chemistry) Urinalysis (Chemistry) The long-term vision for LabSimple is to support all common routine lab tests, and tests that are critical in remote settings with limited access to healthcare. 'The economics and flexibility of LabSimple for the first time enable the business model for a CLIA waived diagnostic platform to become, in many instances, a practical alternative to a central laboratory,' said Scott Kellogg, Chief Business Officer for CLEU. 'Whilst we do not expect to fully replace central lab testing, we do envision a world in which most routine tests are performed on LabSimple, and less common specialty tests are sent to a central lab. This reality may come sooner than people think.' About LabSimple LabSimple is a next generation point-of-care style diagnostic platform designed as an all-in-one replacement for the clinical laboratory while being simple enough for anyone to use without training. LabSimple is disruptive because it has the unusual combination of being comprehensive, high performance, simple, and low cost. LabSimple is a next generation point-of-care style diagnostic platform designed as an all-in-one replacement for the clinical laboratory while being simple enough for anyone to use without training. LabSimple is disruptive because it has the unusual combination of being comprehensive, high performance, simple, and low cost. Building blocks of the LabSimple Platform Accurate multi-functional fluidics programmed for each test panel to automate flow control, degassing, reagent handling, and serial dilution Integration and miniaturization of multiple advanced detection modalities (optical, electrochemical, impedance spectroscopy, microscopy, photometry) Embedded multi-zone temperature control environment Uniquely versatile cartridges to meet requirements of any test panel All with scalable manufacturing at ultra low-cost of goods These building blocks enable a broad range of advanced assay techniques, including chemistry, immunoassay, molecular diagnostics (isothermal / conventional PCR / digital droplet PCR), microscopic image analysis, flow cytometry, & single molecule counting. About CLEU Diagnostics CLEU Diagnostics was founded in 2018 by a group of renowned physicians with the goal of transforming healthcare through innovation. LabSimple is a disruptive, next generation technology that will redefine the $110B US clinical lab testing market. CLEU Diagnostics was founded in 2018 by a group of renowned physicians with the goal of transforming healthcare through innovation. LabSimple is a disruptive, next generation technology that will redefine the $110B US clinical lab testing market. SOURCE: CLEU Diagnostics Copyright Business Wire 2025. PUB: 03/17/2025 07:24 AM/DISC: 03/17/2025 07:25 AM
